p450 - publications
CYP2C19 681G > A polymorphism and pharmacokinetics of clopidogrel in Chinese healthy volunteers.
Pharmazie. 2012 Sep;67(9):795-7
Authors: Zou JJ, Ding L, Tan J, He B, Wang GJ, Wang SK
The aim of this study was to investigate the contribution of the most frequent single nucleotide polymorphism of CYP2C19 681G>A to the pharmacokinetics of clopidogrel in 20 healthy Chinese volunteers after administration of a single dose of clopidogrel 75mg. The peak plasma concentration (Cmax) was higher in the 681GA+681AA group than that in the 681GG group (1.93 +/- 1.77 vs. 1.65 +/- 1.56ng/mL, P=0.613). The area under the curve to the last measurable concentration (AUC(0-36)) and area under the curve extrapolated to infinity (AUC(0-infinity)) of clopidogrel were lower in the 681GG group than that in the 681GA+ 681AA group (2.25 +/- 1.64 vs. 2.64 +/- 1.69 ng h/mL, P = 0.465; 2.26 +/- 1.65 vs. 2.67 +/- 1.71 ng h/mL, P = 0.455) respectively. The oral clearance (CI/F) was lower in the 681GA+681AA group than that in the 681GG group (51.96 +/- 36.13 vs. 54.47 +/- 35.21 x 10(3) L/h, P=0.829). The genetic polymorphism of CYP2C19 681G > A does not cause significant alterations in the pharmacokinetics of clopidogrel at a clinically relevant therapeutic dose in healthy Chinese volunteers.
PMID: 23016454 [PubMed - in process]